2024
Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of protocol S
Shah S, Chou B, Patel M, Watane A, Shah L, Yannuzzi N, Sridhar J. Review and analysis of history and utilization of panretinal photocoagulation and ranibizumab after publication of protocol S. Current Opinion In Ophthalmology 2024, 35: 369-375. PMID: 39115058, DOI: 10.1097/icu.0000000000001076.Peer-Reviewed Original Research
2023
Do published trial results influence physician prescribing patterns? Intravitreal antivascular endothelial growth factor usage by the United States Ophthalmologists before and after Protocol T study
Shah S, Markatia Z, Watane A, Feldman A, Shah L, Sridhar J. Do published trial results influence physician prescribing patterns? Intravitreal antivascular endothelial growth factor usage by the United States Ophthalmologists before and after Protocol T study. Current Opinion In Ophthalmology 2023, 34: 218-225. PMID: 36866850, DOI: 10.1097/icu.0000000000000944.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsBevacizumabDiabetic RetinopathyEndothelial Growth FactorsHumansIntravitreal InjectionsOphthalmologistsPractice Patterns, Physicians'RanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsReview Literature as TopicUnited StatesVascular Endothelial Growth Factor AVisual AcuityConceptsDiabetic macular edemaClinical trial publicationsAflibercept injectionsTrial publicationsAntivascular endothelial growth factor medicationsTreatment of DMEAnti-VEGF agentsGrowth factor usageMacular edemaVEGF agentsLabel bevacizumabT studyTrial resultsBevacizumabYear of publicationMean proportionAverage numberPhysiciansFactor usageTreatmentInjectionIndicationsYearsAfliberceptMedications
2022
Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration
Sood S, Mandell J, Watane A, Friedman S, Parikh R. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology 2022, 140: 716-723. PMID: 35708679, PMCID: PMC9204613, DOI: 10.1001/jamaophthalmol.2022.1819.Peer-Reviewed Original ResearchConceptsRanibizumab port delivery systemPort Delivery SystemBevacizumab injectionIntravitreal ranibizumabNeovascular AMDBimonthly injectionsIntravitreal anti-vascular endothelial growth factor injectionsAnti-vascular endothelial growth factor injectionsIntravitreal anti-VEGF injectionsEndothelial growth factor injectionsTotal direct medical costsAnti-VEGF injectionsIntravitreal bevacizumab injectionGrowth factor injectionsDirect medical costsAge-related macularMedicare reimbursement ratesAflibercept injectionsNeovascular AgeFactor injectionsIntravitreal injectionMacular degenerationMAIN OUTCOMERanibizumabMedical costs
2021
A 5-Year Analysis of Physician-Industry Interactions, Physician Gender, and Anti-VEGF Use in US Ophthalmologists
Watane A, Kalavar M, Patel M, Yannuzzi N, Vanner EA, Kuriyan AE, Sridhar J. A 5-Year Analysis of Physician-Industry Interactions, Physician Gender, and Anti-VEGF Use in US Ophthalmologists. Seminars In Ophthalmology 2021, 36: 804-811. PMID: 34024227, DOI: 10.1080/08820538.2021.1922710.Peer-Reviewed Original Research